Objectives: To describe the population of moderate-to-severe IBS-C patients in French clinical practice and to compare the main data with the European data from the IBIS-C study. The IBIS-C study was conducted in six European countries (France, Germany, Italy, Spain, Sweden and UK). MethOds: Observational, retrospectiveprospective (6 months each) study of patients diagnosed (Rome-III criteria) in the last five years and moderate-to-severe IBS-C severity at inclusion (IBS-Symptom Severity Scale [IBS-SSS] score ≥ 175). Healthcare resource utilisation (HRU) was retrospectively and prospectively assessed and quality-of-life (QoL) was assessed at baseline with IBS-QoL and EuroQoL-5D (EQ-5D). Results: Patient characteristics were similar between the French (n= 59) and European (n= 525) cohorts: mean (±SD) age 47.7±15.7 and 45.3±15.8 years; 83% and 87% were female, and 63% and 60% had severe IBS-C. Mean symptom duration: 13.5±13.5 and 12.8±13.1 years; mean time since diagnosis: 2.6±6.3 and 3.0±5.2 years. At baseline, mean IBS-QoL was 42.9±19.0 and 54.9±22.7 (scale: 0-100[worst-best]); mean EQ-5D was 46.6±22.2 and 55.5±21.7 (scale: 0-100[worst-best]). Over follow-up, 76% French and 73% European patients consulted a GP (mean: 4.2 and 4.9 visits), and 100% and 92% a gastroenterologist (mean: 2.2 and 2.8 visits). 17% and 18% required emergency department visits/hospitalisation (mean stay: 6±6 and 14±24 days). 51% and 65% of patients took prescription drugs for their IBS-C, 61% and 67% took non-prescription drugs. Mean symptom severity (IBS-SSS) improved: 338.9±78.6 (baseline) to 281.5±102.1 (6 months) for the French cohort; 323.2±84.3 to 253.9±105.6 for the European cohort. The total mean (95%CI) annual cost for moderate-to-severe IBS-C was € 4,128 (2,262-6,633) for the French cohort; € 4,639 (3,598) for the European cohort. cOnclusiOns: Moderate-to-severe IBS-C symptoms in France were similar to those other European countries. QoL impairment and HRU were high for both cohorts. Moderate-to-severe IBS-C continued to be a burden for both cohorts with a high economic cost despite availability of therapeutic interventions.
Objectives: To understand medical resource utilisation (MRU) of Australian patients with genotype 1 chronic hepatitis C (GT1 CHC) including those receiving current standard of care treatment (telaprevir or boceprevir with pegylated interferon and ribavirin). MethOds: Medical records were reviewed for a stratified random sample of GT1 CHC patients first attending two liver clinics between 2011 and 2013 (principal population; PP) supplemented by all GT1 CHC patients attending one transplant clinic in the same period (transplant population; TP). CHC-related MRU (percentage and annual rate [poisson] of outpatient, hospitalisation, laboratory and imaging tests) is reported for the PP by treatment status (treated/not treated) stratified by fibrosis grade; and for TP pre-transplant, year of transplant and post-transplant. Results: Comprehensive MRU was collected for 276 PP patients (F0-1 n= 59, F2 n= 58, F3 n= 53, F4 n= 106; 38 were treatment experienced prior to first visit; mean follow-up 17.6 months). Fifty-five (19.9%) received triple therapy. Data were collected for 112 TP patients (mean follow-up 29.9 months), 33 (29.5%) received a transplant during the study and 51 (45.5%) beforehand. MRU was higher while treated including annual rates of outpatient visits (PP: 9.67 vs 2.91 [F0-1 2.60, F2 2.56, F3 2.63, F4 3.33]; TP: transplant 18.00 vs pre 5.55, post 5.14), psychiatric visits (PP: 0.71 vs 0.18 [F0-1 0.25, F2 0.16, F3 0.20, F4 0.14]; TP: transplant 0.00 vs pre 0.50, post 0.01), nurse visits (PP: 1.84 vs 0.42 [F0-1 0.58, F2 0.42, F3 0.51, F4 0.32]); and the percentage with hospitalisation (PP: 27.3% vs 13.0% [F0-1 3.4%, F2 10.3%, F3 9.4%, F4 21.7%]; TP: transplant 100% vs pre 96.5%, post 79.2%). cOnclusiOns: CHC-related MRU increases substantially with disease severity. To our knowledge, these are the first real-world MRU reported for GT1 CHC in Australia and will be valuable in assessing the impact of new hepatitis C treatments.
PGI58 healTh TeChnoloGy aSSeSSMenT In ChronIC hePaTITIS C: aSSeSSMenT of deCISIon landSCaPe and ManufaCTurer InPuTS In SIx aGenCIeS
Mazumder D 1 , Kapoor A 1 , Gwatkin N 2 , Medeiros C 3 1 Optum Global Solutions, Noida, India, 2 Geni Biopharma, Hampshire, UK, 3 Optum Life Sciences, Minneapolis, MN, USA Objectives: To evaluate the landscape of health technology assessment (HTA) decisions for chronic hepatitis C (CHC) therapies in Canada (CADTH), Australia (PBAC), England and Wales (NICE), Scotland (SMC), Germany (IQWiG), and France (HAS). MethOds: Selected HTA agency websites were searched for submissions made in the CHC therapy area. Submissions were searched for following information: clinical and economic input provided in the submission, recommendations from HTA agencies, and drivers of HTA decisions. Results: Victrelis®, Daklinza®, Roferon A®, Intron A®, Harvoni®, Viekirax®, Pegasys RBV®, PegIntron®, Rebetol®, Olysio®, Sovaldi®, and Incivo® were the pharmacotherapies for which manufacturer submissions were available across selected agencies. The number of HTA submissions with completion status ranged from 6-12. The percentage recommendation ranged from 43% in Australia to 100% in France and Canada. The number of clinical studies supporting the manufacturer submission ranged from 2-12. The status, and treatment patterns. Physicians were screened for duration of practice (≥ 3yrs) and patient volume (≥ 15 HCV patients/mo) and recruited from a large panel to be geographically representative. Medical charts of the next 10 consecutive HCV patients were abstracted. G1 HCV patient data was analyzed. Results: 2067 eligible G1 HCV patients were included in the analysis (France:374/Germany:506/Italy:412/Spain:475/UK:300). Patient characteristics included (France/Germany/Italy/Spain/UK) -mean age (yrs):53/49/55/52/45; male: 61%/67%/61%/59%/69%; patient weight < = 80kg:81%/66%/83%/74%/76%; majority were G1-subtype A (52%/44%/31%/34%/68%) or B (48%/54%/68%/66%/32%); any substance-abuse:23%/18%/10%/17%/47%; route of infection via intravenous drug use:55%/33%/31%/41%/69%, via blood transfusion:19%/26%/21%/36%/7%, via heterosexual contact:5%/11%/22%/11%/7%, via homosexual contact:8%/13%/10%/6%/12%; current fibrosis scores were -F0:9%/18%/6%/7%/20%, F1:18%/30%/25%/25%/32%, F2:24%/28%/32%/24%/18%, F3:21%/17%/17%/20%/11%, F4:29%/6%/20%/23%/19%. In France/Germany/Italy/Spain/UK, latest mean alanine aminotransferase levels were:58/90/95/62/73; patients with undetectable (0-500) viral load (VL):5%/2%/25%/2%/1%; 501-< = 1Million VL-count:58%/39%/52%/75%; > 1M VL-count:38%/26%/38%/45%/25%. Treatment patterns included (France/Germany/ Italy/Spain/UK)-currently treated:23%/28%/20%/17%/20%, not currently treated (previous treatment non-responder, discontinued or relapsed, or therapy complete and awaiting sustained viral response):21%/20%/29%/30%/22%, not current treated because patient achieved sustained viral response:19%/12%/11%/13%/6%; treatment naïve/never been treated:38%/40%/41%/41%/52%. cOnclusiOns: In this cohort of G1 HCV patients, treatment rates and disease burden varied among studied countries in EU; only a small proportion of patients had undetectable VL or was not treated owing to achieving sustained viral response. Further research is warranted to assess the observed treatment patterns, effectiveness of regimens, and patient management strategies to alleviate patient burden.
PGI54 ProTon PuMP InhIBITorS In ITaly: IT'S TIMe To Make a (PolICy) ChanGe
Lidonnici D 1 , Lanati EP 2 1 3Pharma Consulting Boutique Sagl, Lugano, Switzerland, 2 MA Provider Srl, Milano, Italy Objectives: The analysis aimed to evaluate the evolution of the national and regional public expenditure regarding Proton Pump Inhibitors (PPIs) in Italy, in relation to national and regional policies. MethOds: The analysis combined data published by the Italian Medicines Agency (AIFA) and Regions and regional and national laws, to understand the impact of the applied policies on PPIs expenditure. Results: Over the past ten years, PPIs consumption increased by 280% (around 14% yearly), with lansoprazole reaching +533%. The number of patients ≥ 18 treatable with PPIs in 2013 was 2.873.500 (6% of adult population), being the first class in terms of expenditure with a per capita value of 15.2€ and consumptions of 74 DDD/1.000 inh./die. Consumptions and expenditure incresed by respectively 6.5% and 1.6% vs 2012. AIFA also highlighted a trend to prescriptive inappropiateness over the years, where the 46.5% of patients do not meet the reimbursability criteria by law. At regional level, Regions have issued a number of regional laws to contain both consumptions and expenditure (e.g. through reference pricing or guidelines to encourage the prescription of genericated drugs), identifying specific performance indicators and target values. We estimated potential savings from the correct application of the reimburability criteria amounting to 260 million € /year, if Regions were able to control prescriptive appropriateness, to which additional savings could be added through focused cost-containment measures. cOnclusiOns: Despite a number of efforts at both central and regional level, the trend towards inappropriateness and expenditure increase of PPIs is confirmed. A review of both national and regional policies on PPIs expenditure is key to reduce the current waste of economic resources and, with a stable total budget, guarantee additional funding for innovation. Objectives: Comprehensive assessment of the financial costs of drug treatment of nonalcoholic steatohepatitis (NASH) in a hospital of Kharkiv, Ukraine. MethOds: For the study, the schemes medicinal histories of 54 patients with NASH in a hospital in Kharkov during 2013 were used. The structure of costs of NASH treatment was assessed by the ABC analysis. Assessment of the level of NASH treatment correspondence was conducted by the formal VEN analysis according to the National Drug Formulary (NDF) of Ukraine (2013). Index "V" was put in case of availability of the drug in the NDF, index "N" -in case of its absence. Directions of NASH treatment were assessed by the prescriptions of drugs according to requirements of Ukrainian Cinical Guidelines (O.Ia. Babak, 2007) and according to Practice Guideline by the American Association for the Study of Liver Diseases (AASLD) for 2012. In determining the cost of drugs, their prices as of May 2015 by the data of Morion reference and retrieval system "Drugs" were used. Results: Drug treatment of patients with NASH by pharmacotherapeutic groups met the basic requirements of Ukrainian Clinical Guidelines and Guidelines of American scientists AASLD, which confirms the rationality of prescriptions. According to the ABC/VEN analysis, most of the funds for treatment (82%) were spent on 76% of drugs included in the NDF. But 24% of drugs were missing from the NDF of Ukraine, indicating the need to correct NASH treatment in the hospital of Ukraine. cOnclusiOns: 76% of drugs prescribed to patients with NASH can be considered rational, but 24% of drugs had index "N", indicating their inappropriate use. Comparison of the ABC and VEN analysis showed the need to correct NASH treatment in the hospital of Ukraine, as 18% of funds were spent on minor drugs which are not represented the NDF of Ukraine.
PGI55 aSSeSSInG The raTIonalITy of CoSTS of druG TreaTMenT of nonalCoholIC STeaTohePaTITIS In The hoSPITal of ukraIne
Objectives: To review clinical guidelines, recent HTA decisions, and the influence of economic analyses in HTA decisions related to biologic therapies in UC. MethOds: A literature review and targeted research provided information on clinical treatment guidelines (US and Europe) and HTAs (Europe) related to biologics in UC. Economic models in UC were identified and reviewed to determine how these affected HTA decisions. Results: Since several biologics were approved after the last version of the US treatment guidelines, the US guidelines only address the use of infliximab for the treatment of moderate or severe UC. In the UK, NICE has recommended infliximab, adalimumab, and golimumab as possible treatments for adults with moderate to severe UC in whom conventional therapy hasn't worked or isn't suitable. A recent NICE HTA recommends vedolizumab as an option for treating moderately to severely active UC in adults only if the company provides vedolizumab with the discount agreed in the patient access scheme. The Scottish Medicines Consortium (SMC) recommends vedolizumab for the treatment of adult patients with moderate-to-severe UC and an inadequate response, lost response, or intolerance to conventional therapy or a TNFα antagonist; this advice is "contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower." Earlier SMC advice did not recommend adalimumab, golimumab or infliximab for use within NHS Scotland due to lack of robust economic analyses. The SMC advice is superseded by the NICE HTA decisions. cOnclusiOns: In the UK and Scotland, more than 9 HTA have been performed in the 10 years since biologics have become available for the treatment of moderate-to-severe UC. Differential cost-effectiveness among specific indications, lines of treatment, and countries have resulted in a variety of recommendations as to their use which supplement clinical guidelines in UC.
PGI62 doSe eSCalaTIon aMonG ulCeraTIve ColITIS PaTIenTS TreaTed wITh adalIMuMaB In Sweden
Salomonsson S 1 , Söderberg J 2 , Alenadaf K 2 , Ljung T 1 1 Merck Sharp & Dohme, Stockholm, Sweden, 2 Health Solutions, Stockholm, Sweden Objectives: The objective of this study was to describe the real-world use of adalimumab (ADA) for maintenance treatment of ulcerative colitis (UC) on a national level in Sweden. MethOds: A longitudinal, retrospective cohort study was conducted using the National Drug Registry and the National Patient Registry. UC patients (age ≥ 18 years) treated with ADA were included. Two cohorts were selected: (1) ADA naïve patients and (2) a cross-sectional cohort. Both cohorts were followed for a 12-month period. Dose escalation among the ADA naïve patients was defined as doubling of dose (ADA 40 mg every week) or having two following filled prescriptions with average biweekly dose (ABD) ≥ 50 mg. Dosing in the cross-sectional cohort was assessed studying annual number of injections dispensed among patients on maintenance treatment. Results: Five hundred and eighty-seven patients were identified as ADA naive during Jan 2010-April 2014. Dose-escalation by doubling of dose was observed in 273 (46.5%) patients with the median time to dose escalation being 84 days. Further analysis revealed that 191 patients (32.5%) in the ADA naive patient cohort dose-escalated defined as (ABD) ≥ 50 mg, and of these 40 (20.9%) had a subsequent dose de-escalation which occurred after a median time of 162 days. In total 992 UC patients were identified in the cross-sectional cohort, defined as filling at least one prescription during May 2013-April 2014, and of these 364 (37%) were on maintenance treatment. Out of the 364 patients on maintenance treatment dispensing at least 22 injections during the period 140 (38%) received 30 injections or more. cOnclusiOns: This study demonstrates that UC patients receiving ADA in general have a patchy prescription pattern, and that the proportion of patients who dose escalate is high. This finding and the impact that dose escalation has on costs may have implications for healthcare professionals and budget holders.
PGI63 effeCTS of fInanCIal InCenTIveS for SavInG druG exPendITureS on PhySICIan PreSCrIPTIon BehavIorS
Park S 1 , Han E 2 1 Korea Institue for Health and Social Affairs, Sejong, South Korea, 2 Yonsei University, Incheon, South Korea Objectives: The purpose of this study is to assess the impact on physician prescription behaviors of an outpatient prescription incentive program providing financial rewards to primary care physicians for saving prescription costs implemented in October 2010 in South Korea. MethOds: A 10% sample of clinics (N= 1,625) was randomly selected from the entire clinics in the National Health Insurance claims database for the years 2009~2012, and all claims with the primary diagnosis of peptic ulcer or gastro-esophageal reflux diseases were extracted from those clinics' data. We used a clinic-level random effects model analyzing policy effects on drug expenditures and prescribing behaviors including prescription rate of medicines treating target diseases, number of drug prescribed per claim, prescription duration per claim. We also performed subgroup analyses by selected clinic characteristics, including practice type, size and specialty. Results: We found no significant impact of the program on drug expenditure overall. Prescription rate of target medicines increased and the average prescription duration per claim decreased after the incentive program. After the financial incentive program, clinics in general medicine showed a lower prescription rate (by 0.8 percentage points), lower number of medicines prescribed (by 0.02), a lower prescription duration (by 0.15 days), and lower drug expenditure per claim after the policy (by 740 won). Small clinics had shorter prescription duration (by 0.76 days), while large clinics and clinics in group practice had a higher prescription rate (by 1.5 and 2.5 percentage points, respectively) and higher number of medicines prescribed (by 0.03 for group practice only) after the program. cOnclusiOns: The financial incentive program worked as intended only in certain subgroup clinics for the target medicines. The reduction in prescription duration and the number of prescribed medicines in target claims in selected subgroups imply some margin for prescription adjustments. quality of clinical evidence originating from same studies has been rated differentially by different agencies. The economic evidence in this area was primarily based on cost-effectiveness/cost utility analysis (CEA/CUA), comprising ~95% of studies (time horizon 50 years to lifetime). The incremental cost-effectiveness ratios (ICER) ranged USD15000-200000 in PBAC, USD1246-376723 in NICE, USD750-45200 in SMC, and USD11000-75000 in CADTH. More than 90% of the decisions based on ICER values were positive, with restriction being focused on cost negotiations. The primary driver of positive decisions was majorly economic analysis in NICE, PBAC, and SMC, while clinical evidence drove positive recommendations in CADTH, IQWiG, and HAS. cOnclusiOns: Current landscape of CHC treatments in Canada, Australia, UK, Scotland, Germany, and France is majorly dominated by positive recommendations, considering the high unmet in this area. Most of the restrictions were around cost negotiations. The drivers of decisions fit with agency priorities, with economic analysis being the key driver in agencies with pharmacoeconomic analysis, and clinical evidence in agencies without pharmacoeconomic analysis.
PGI59

CoMParISon of reGulaTory laBelS and hTa deCISIonS for ChronIC hePaTITIS-C TheraPIeS
Banerjee P 1 , Kapoor A 1 , Mazumder D 1 , Gwatkin N 2 , Medeiros C 3 1 Optum Global Solutions, Noida, India, 2 Geni Biopharma, Hampshire, UK, 3 Optum Life Sciences, Minneapolis, MN, USA Objectives: To compare the regulatory label indications and health technology assessment (HTA) recommendations for therapies indicated for the treatment of chronic hepatitis-C (CHC). MethOds: We reviewed the regulatory labels approved by European Medicines Agency (Europe), Health Canada (Canada) and Therapeutic Goods Administration (Australia). HTA reports for CHC therapies published by NICE (England and Wales), SMC (Scotland), HAS (France), IQWiG (Germany), CADTH (Canada) and PBAC (Australia) were assessed. Therapies with a positive HTA decision (recommended or restricted) were included in the analysis. Indication was split into four categories: age of the population (children, adults or both), fibrosis status (cirrhotic or non-cirrhotic), genotype, and prior treatment history (naïve or treatment-experienced). A match was defined as overlap of HTA and regulatory decision for any of the categories. Percentage correlation of the HTA indication with the regulatory label was calculated as the ratio of actual matches to the maximum possible matches for the parameters considered. Results: A total of 34 regulatory approvals and 48 HTA reports were identified from the public domain. Forty-six HTA reports providing a positive decision were included. Overall, HTA decisions correlated well with the marketing authorization (89%), with the highest correlation observed for CADTH and PBAC (100% each), followed by HAS (98%), NICE and SMC (86% each) and IQWiG (63%). Across agencies, highest correlation was observed for age of the population (96% cases) and lowest for the prior treatment history (85% cases) of the population for whom the therapies were recommended. cOnclusiOns: Overall, the indication approved by HTA agency almost correlated completely with the indication granted marketing authorization, except for NICE, SMC and IQWiG, indicating difference in agency priorities driving HTA decisions. Analyzing the population restriction applied by NICE, SMC and IQWiG would provide the decision drivers, allowing manufacturers to address these concerns in prospective submissions.
PGI60 TrendS In healTh TeChnoloGy aSSeSSMenT deCISIonS aCroSS The GloBe: a foCuS on hePaTITIS C
Clark RS, Meyer KL, Bramley TJ Xcenda, Palm Harbor, FL, USA Objectives: Recent advances in the management of hepatitis C virus (HCV) have yielded therapeutic modalities that are more efficacious, better tolerated, and have a lower pill and injection burden. Given the large population affected by HCV, decisions by health technology assessment (HTA) bodies weigh significantly in terms of societal benefits and expenditures. The objective of this analysis was to evaluate recent patterns in HCV-related HTA decisions in selected countries. MethOds: HTA surveillance was conducted for Australia, Canada, France, Germany, and the United Kingdom (UK) from January 1, 2012 to June 1, 2015 (42 months). HTAs for HCV treatments were evaluated by genotype, decision, and decision rationale. Decisions were categorized as favorable, unfavorable, mixed (both favorable and unfavorable), and neutral (deferral). Results: 32 HCV-related HTAs were published in the study time frame, with 7 assessments currently in development. Among the completed assessments, the majority of decisions were favorable (24, 75%), with only 2 (6%) unfavorable and 6 (19%) mixed decisions. The most common rationales provided for a negative decision included insufficient data and/ or inappropriate comparators (4), insufficient benefit to justify the high cost (ie, improperly high incremental cost-effectiveness ratio [ICER]) (3), and inadequate clinical benefit vs the most appropriate comparator (1). France and Canada had the highest percentage of favorable decisions (5 of 5 and 9 of 9, respectively, 100%), followed by the UK (3 of 4, 75%), Australia (5 of 8, 63%), and Germany (2 of 6, 33%). cOnclusiOns: Based on the last 42 months of HCV-related HTAs, 75% of decisions were favorable. However, the most significant factors leading to unfavorable assessments for HCV products are related to the inability to supply advantageous clinical and cost-effectiveness data. This analysis suggests that manufacturers would have greater success with HTA decisions if more robust health economic and clinical data are generated.
